Pro-график

Lakewood-Amedex Biotherap...

NasdaqCM: LABT · Цена в реальном времени · USD
2.27
-0.06 (-2.58%)
На закрытии: Aug 14, 2026, 3:59 PM
2.17
-4.32%
Постмаркет: 7:59 PM

Описание компании

Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States. The company offers products from its Bisphosphocin class, a novel class of antimicrobial agents a broad range of infections, including those affecting the skin, bladder, and lungs. It also develops Nu-3, a topical antimicrobial for infected diabetic foot ulcers, which is in Phase 2b clinical trial. The company was formerly known as Lakewood-Amedex Inc. and changed its name to Lakewood-Amedex Biotherapeutics, Inc. in June 2025. Lakewood-Amedex Biotherapeutics, Inc. was incorporated in 2006 and is headquartered in University Park, Florida.

Lakewood-Amedex Biotherapeutics Inc.
Lakewood-Amedex Biotherapeutics Inc. logo
СтранаUnited States
Дата IPO23 апр. 2026 г.
ОтрасльBiotechnology
СекторHealthcare
Сотрудники5
CEODr. Kelvin Cooper Ph.D.

Контакты

Адрес:
8031 Cooper Creek Blvd.
University Park, FL
United States
Сайтhttps://lakewoodamedex.com

Данные по акции

ТикерLABT
БиржаNasdaqCM
Финансовый годJan '25 - Dec '25
Валюта отчётностиUSD
Код CIK0002079272
Номер CUSIPn/a
Номер ISINn/a
Employer IDn/a
Код SICn/a

Ключевые руководители

ИмяДолжность
Dr. Kelvin Cooper Ph.D.CEO, SVP of Research & Development and Director
Mr. Peter F. CeccacciCFO & VP of Administration
Dr. Thomas Balzer M.D., Ph.D.Chief Medical Officer & SVP of Clinical Development
Ms. Tara EndressProject Manager & Accounting Manager
Daniel Kontoh-BoatengInvestor Relations

Последние отчёты SEC

Отчётов SEC нет.